Glenmark Life Sciences Limited

1,082.6

INR
+22.85(+2.16%)
As of November 14, 2024 10:00:00 AM

About Glenmark Life Sciences Limited

Glenmark Life Sciences Limited engages in the development, manufacture, and marketing of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. The company offers various APIs, such as olmesartan, telmisartan, perindopril, atovaquone, solifenacin, mirabegron, sitagliptin, zonisamide, adapalene, and rosuvastatin. It also provides contract development and manufacturing services to a range of multinational corporations and specialty companies. The company's APIs are used in various therapeutic segments, including cardiovascular disease, central nervous system disorders, diabetes, gastrointestinal health, oncology, pain management, and anti-infectives. It also exports its products to Europe, North America, Latin America, Japan, and internationally. The company was incorporated in 2011 and is based in Mumbai, India. Glenmark Life Sciences Limited is a subsidiary of Nirma Limited.

RevenueLast 12 months
NA
+NA YoY
EBITDALast 12 months
NA
Price to Sales RatioTTM
5.71x
Operating MarginLast 12 months
23.53
+-19.7% quarterly YoY
Market Cap
12589.65 CrINR
Employees
2014
CEO
Dr. Yasir Yusufali Rawjee Ph.D.
Website

Glenmark Life Sciences Limited

1,082.6

INR
+22.85(+2.16%)
As of November 14, 2024 10:00:00 AM

About Glenmark Life Sciences Limited

Glenmark Life Sciences Limited engages in the development, manufacture, and marketing of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. The company offers various APIs, such as olmesartan, telmisartan, perindopril, atovaquone, solifenacin, mirabegron, sitagliptin, zonisamide, adapalene, and rosuvastatin. It also provides contract development and manufacturing services to a range of multinational corporations and specialty companies. The company's APIs are used in various therapeutic segments, including cardiovascular disease, central nervous system disorders, diabetes, gastrointestinal health, oncology, pain management, and anti-infectives. It also exports its products to Europe, North America, Latin America, Japan, and internationally. The company was incorporated in 2011 and is based in Mumbai, India. Glenmark Life Sciences Limited is a subsidiary of Nirma Limited.

RevenueLast 12 months
NA
+NA YoY
EBITDALast 12 months
NA
Price to Sales RatioTTM
5.71x
Operating MarginLast 12 months
23.53
+-19.7% quarterly YoY
Market Cap
12589.65 CrINR
Employees
2014
CEO
Dr. Yasir Yusufali Rawjee Ph.D.
Website